Casdin Capital, LLC
An institutional investment manager in New York, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1534261.
- Reported value$2.00bn
- Positions43
Holdings: 43 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Revolution Medicines IncRVMD | COM | 76155X100 | 483 | 24.2% | 2,577,333 | Unchanged | |
| Relay Therapeutics IncRLAY | COM | 75943R102 | 300 | 15.0% | 16,035,240 | Added+1,616,666 | |
| Genedx Holdings CorpWGS | COM CL A | 81663L200 | 254 | 12.7% | 3,707,164 | Added+700,000 | |
| Biolife Solutions Inc | COM NEW | 09062W204 | 131 | 6.6% | 4,655,000 | Reduced−1,302,165 | |
| Illumina IncILMN | COM | 452327109 | 93.2 | 4.7% | 530,000 | Unchanged | |
| Standard Biotools IncLAB | COM | 34385P108 | 73.0 | 3.7% | 88,783,856 | Unchanged | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 63.1 | 3.2% | 1,175,000 | Unchanged | |
| Denali Therapeutics IncDNLI | COM | 24823R105 | 52.6 | 2.6% | 2,045,000 | Added+205,000 | |
| Neurogene IncNGNE | COM | 64135M105 | 48.6 | 2.4% | 1,545,361 | Added+125,000 | |
| Beam Therapeutics IncBEAM | COM | 07373V105 | 46.3 | 2.3% | 1,350,000 | Unchanged | |
| 10X Genomics IncTXG | CL A COM | 88025U109 | 40.3 | 2.0% | 1,050,000 | Reduced−1,225,000 | |
| Scholar Rock HLDG CorpSRRK | COM | 80706P103 | 36.6 | 1.8% | 665,000 | Added+315,000 | |
| Personalis IncPSNL | COM | 71535D106 | 34.2 | 1.7% | 2,550,000 | Added+950,000 | |
| Grail IncGRAL | COM | 384747101 | 32.8 | 1.6% | 480,000 | Added+250,000 | |
| Guardant Health IncGH | COM | 40131M109 | 27.8 | 1.4% | 185,000 | Reduced−130,000 | |
| Maze Therapeutics IncMAZE | COM | 578784100 | 25.2 | 1.3% | 843,857 | Added+85,000 | |
| Hims & Hers Health IncHIMS | COM CL A | 433000106 | 24.3 | 1.2% | 700,000 | Unchanged | |
| Alnylam Pharmaceuticals IncALNY | COM | 02043Q107 | 22.6 | 1.1% | 75,000 | Unchanged | |
| Taysha Gene Therapies IncTSHA | COM SHS | 877619106 | 22.1 | 1.1% | 3,250,000 | Unchanged | |
| Agomab Therapeutics NVAGMB | SPONSORED ADS | 00860C102 | 20.1 | 1.0% | 1,550,000 | Unchanged | |
| Septerna IncSEPN | COM | 81734D104 | 18.5 | 0.9% | 553,268 | Unchanged | |
| Parabilis Medicines IncPBLS | COM | 698955101 | 17.7 | 0.9% | 645,690 | New+645,690 | |
| Sionna Therapeutics IncSION | COM | 829401108 | 17.6 | 0.9% | 400,000 | New+400,000 | |
| Veracyte IncVCYT | COM | 92337F107 | 16.2 | 0.8% | 276,308 | Unchanged | |
| Adlai Nortye LtdANL | SPONSORED ADS | 00704R109 | 14.4 | 0.7% | 1,250,000 | Added+711,539 | |
| Prime Medicine IncPRME | COM | 74168J101 | 11.7 | 0.6% | 3,167,175 | Unchanged | |
| Absci CorporationABSI | COM | 00091E109 | 11.3 | 0.6% | 973,260 | Unchanged | |
| Quest Diagnostics IncDGX | COM | 74834L100 | 10.6 | 0.5% | 50,000 | Unchanged | |
| Sarepta Therapeutics IncSRPT | COM | 803607100 | 8.4 | 0.4% | 470,000 | New+470,000 | |
| Uniqure NV | SHS | N90064101 | 6.9 | 0.3% | 150,000 | New+150,000 | |
| Intellia Therapeutics IncNTLA | COM | 45826J105 | 6.0 | 0.3% | 355,000 | Unchanged | |
| Moderna IncMRNA | COM | 60770K107 | 5.3 | 0.3% | 75,000 | Unchanged | |
| Disc Medicine IncIRON | COM | 254604101 | 4.8 | 0.2% | 65,000 | Unchanged | |
| Monte Rosa Therapeutics IncGLUE | COM | 61225M102 | 4.5 | 0.2% | 186,014 | Unchanged | |
| Century Therapeutics IncIPSC | COM | 15673T100 | 3.0 | 0.2% | 1,228,190 | Unchanged | |
| Contineum Therapeutics IncCTNM | CL A | 21217B100 | 2.4 | 0.1% | 148,333 | Unchanged | |
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 2.2 | 0.1% | 282,312 | Unchanged | |
| Editas Medicine IncEDIT | COM | 28106W103 | 1.4 | <0.1% | 445,000 | New+445,000 | |
| Pacific Biosciences Calif inPACB | COM | 69404D108 | 1.2 | <0.1% | 723,767 | Unchanged | |
| Kardigan IncKARD | COM | 485925101 | 1.2 | <0.1% | 50,000 | New+50,000 | |
| Recursion Pharmaceuticals inRXRX | CL A | 75629V104 | 0.6 | <0.1% | 165,323 | Unchanged | |
| Ginkgo Bioworks Holdings IncDNA | CL A NEW | 37611X209 | 0.4 | <0.1% | 36,493 | Unchanged | |
| Tenaya Therapeutics IncTNYA | COM | 87990A106 | 0.3 | <0.1% | 361,969 | Unchanged |
Sold out: 3 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Moonlake ImmunotherapeuticsMLTX | CLASS A ORD | 61559X104 | 0.0 | 0.0% | 0 | Sold out−450,000 | |
| Qiagen NV | ORD SHARES | N72482156 | 0.0 | 0.0% | 0 | Sold out−360,000 | |
| Tempus Ai IncTEM | CL A | 88023B103 | 0.0 | 0.0% | 0 | Sold out−294,127 |
Source: SEC EDGAR, Form 13F-HR, accession 0000919574-26-005491 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.